In the assessment of risks of cardiovascular diseases associated with antidiabetic drugs in patients with type 2 diabetes, Ou et al. found that DPP-4 inhibitor users had a significantly lower risk for MACE, stroke, myocardial infarction, and HF than that of meglitinides and insulin, but higher than that of metformin users (Ou et al., 2016). This evidence concerns the gene DPP4 and type 2 diabetes mellitus.